While, targeting HIF1 and other associated potential biomarkers may in fact reduce mortality associated with breast cancer in diabetic patients, eventually alleviating the socioeconomic burden of diabetes- breast cancer association on global health. This evidence concerns the gene HIF1A and breast carcinoma.